Try our beta test site

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01857193
First received: May 16, 2013
Last updated: February 21, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 28, 2018
  Estimated Primary Completion Date: September 28, 2018 (Final data collection date for primary outcome measure)